Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Successful treatment of relapsed FLT3-mutated donor cell-derived MDS/AML with FLT3 inhibitor gilteritinib.

Annals of hematology - 23 Feb 2026

Kawano Mana, Kunimoto Hiroyoshi, Izumi Akihiko, Adachi Akiko, Miura Ayaka, Yokoyama Chiaki, Hasegawa Kodai, Shirafuta Mayoko, Tanaka Marika, Sakuma Takayuki, Ohashi Takuma, Takahashi Hiroyuki, Miyazaki Takuya, Tachibana Takayoshi, Hagihara Maki, Matsumoto Kenji, Nakajima Hideaki

Abstract excerpt

Donor cell-derived myelodysplastic syndrome/acute myeloid leukemia is a rare but serious complication of allogeneic hematopoietic stem cell transplantation, and its optimal treatment has not been established. Here, we report a case of a 44-year-old woman who was diagnosed with donor cell-derived myelodysplastic syndromes with excess blasts carrying RAD21 and KMT2D mutations after six-year clinical remission of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to fms-Like Tyrosine Kinase 3
Share to FLT3 gene

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Hematopoietic Stem Cell Transplantation

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Myelodysplastic Syndromes

Share to Protein Kinase Inhibitors

Share to Recurrence

Source

Open in PubMed Open full text

Identifiers

PMID: 41729290
DOI: 10.1007/s00277-026-06896-3
PMCID: PMC12929219

Genes

FLT3
KMT2D
RAD21

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Successful treatment of relapsed FLT3-mutated donor cell-derived MDS/AML with FLT3 inhibitor gilteritinib.PMID 41729290Read ↗

Successful Pre- and Post-transplant Administration of Gilteritinib in a Patient with Relapsed and Refractory Acute Myeloid Leukemia Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation.Semantic proximity Read ↗

Successful treatment with gilteritinib for isolated extramedullary relapse of acute myeloid leukemia with FLT3-ITD mutation after allogeneic stem cell transplantation.Semantic proximity Read ↗

Successful treatment with gilteritinib for popliteal extramedullary relapse of FLT-3-ITD acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation : a case report and literature reviewSemantic proximity Read ↗

Successful bridge therapy of gilteritinib to cord blood transplantation in relapsed acute myeloid leukemia after bone marrow transplantation.Semantic proximity Read ↗

Triplet therapy with gilteritinib, venetoclax, and azacitidine for relapsed/refractory FLT3mut acute myeloid leukemia.Semantic proximity Read ↗

Gilteritinib: An FMS-like tyrosine kinase 3/AXL tyrosine kinase inhibitor for the treatment of relapsed or refractory acute myeloid leukemia patients.Semantic proximity Read ↗

Gilteritinib maintenance after allogeneic hematopoietic stem cell transplantation for relapsed/refractory acute myeloid leukemia with FLT3-internal tandem duplication mutationSemantic proximity Read ↗

Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML.Semantic proximity Read ↗

Long-term outcomes of azacitidine, venetoclax, and gilteritinib in newly diagnosed FLT3-mutated AML.Semantic proximity Read ↗

Maintenance Treatment With Gilteritinib Suppresses Post-transplant Relapse in Relapse/Refractory FLT3-Mutated Acute Myeloid Leukemia.Semantic proximity Read ↗

[Gilteritinib for pediatric FLT3 internal tandem duplication-positive recurrent acute myeloid leukemia].Semantic proximity Read ↗

Gilteritinib enhances graft-versus-leukemia effects against FLT3-ITD mutant leukemia after allogeneic hematopoietic stem cell transplantation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.